Solute carrier membrane transporters (SLCs) control cell exposure to small-molecule drugs, thereby contributing to drug efficacy and failure and/or adverse effects. Moreover, SLCs are genetically linked to various diseases. Hence, in-depth knowledge of SLC function is fundamental for a better understanding of disease pathophysiology and the drug development process. Given that the model organism Drosophila melanogaster (fruit fly) expresses SLCs, such as for the excretion of endogenous and toxic compounds by the hindgut and Malpighian tubules, equivalent to human intestine and kidney, this system appears to be a promising preclinical model to use to study human SLCs. Here, we systematically compare current knowledge of SLCs in Drosophila and humans and describe the Drosophila model as an innovative tool for drug development.

溶质载体膜转运蛋白（SLC）控制细胞与小分子药物的接触，从而促进药物功效，失败和/或不良影响。此外，SLC在遗传上与各种疾病有关。因此，深入了解SLC功能对于更好地了解疾病的病理生理学和药物开发过程至关重要。假设模型生物果蝇（果蝇）表达SLC，例如通过后肠和Malpighian小管排泄内源性和有毒化合物，相当于人的肠和肾，则该系统似乎是有希望的临床前模型，可用于研究人类SLC。在这里，我们系统地比较果蝇和人类中SLC的当前知识，并描述果蝇模型作为药物开发的创新工具。